Immunotherapy Coverage from Every Angle

Recent News

AACR 2021: Overall Survival Update From IMmotion151 in Advanced Kidney Cancer
AACR 2021: Adding Nivolumab to Neoadjuvant Platinum-Doublet Chemotherapy for NSCLC
AACR 2021: Is Pembrolizumab Effective in Treating Advanced Cutaneous Squamous Cell Carcinoma?
AACR 2021: T-Cell Infusion Product Under Investigation in Resistant CLL
AACR 2021: Survival Outcomes by Treatment Response From IMvigor130 in Urothelial Cancer
Green Tea Treatment in Elderly Patients With Myelodysplasia-Related AML
AACR 2021: Combination Targeted Therapies Under Study in Resistant Kidney Cancer
Is Adjuvant Atezolizumab Safe and Effective in Muscle-Invasive Urothelial Cancer?
AACR 2021: Nivolumab Plus Ipilimumab in Biomarker-Selected Patients With Metastatic Prostate Cancer
ICER Releases Evidence Report on BCMA Therapies for Multiple Myeloma
Response to Induction Therapy and Ofatumumab Consolidation in Patients With CLL
Sacituzumab Govitecan-hziy Receives Regular FDA Approval for Triple-Negative Breast Cancer
Novel Agent Under Study in CLL: Dual Inhibitory Activity Reported
Daratumumab-Based Therapy for Myeloma: Patient-Reported Outcomes From CASTOR Trial
Adjuvant Durvalumab for Localized Urothelial Cancer
KEYNOTE-355 Update on Pembrolizumab in Triple-Negative Breast Cancer
IGLL5 Expression in Clear Cell Kidney Cancer: Potential Prognostic Biomarker?
FDA Approves First Cell-Based Gene Therapy for Multiple Myeloma
High-Risk CLL: GENUINE Trial of Ublituximab Plus Ibrutinib Versus Ibrutinib Alone
Novel Vaccine Under Study in Basal Cell Carcinoma
Early Access Treatment Protocol of Daratumumab in European and Russian Patients With Resistant Myeloma
BTK Inhibitor and Cerebral Invasive Aspergillosis: Case Report in CLL
Miami Breast Cancer Conference 2021: DESTINY-Breast01 Trial Update on Trastuzumab Deruxtecan-nxki
CLEAR Trial: Targeted Therapy Plus Immunotherapy in Advanced Renal Cell Carcinoma
Avelumab Plus Hypofractionated Radiotherapy for Resistant Multiple Myeloma
Cardiac Repolarization After Daratumumab Monotherapy for Smoldering Multiple Myeloma
KEYNOTE-365 Update on Pembrolizumab Plus Chemotherapy for Metastatic Prostate Cancer
Idecabtagene Vicleucel Under Study in Relapsed and Refractory Multiple Myeloma
Comparing Immunotherapy Regimens in Metastatic Kidney Cancer
Cemiplimab-rwlc Monotherapy and PD-L1 Expression in Advanced NSCLC
Margetuximab-cmkb Versus Trastuzumab in ERBB2-Positive Advanced Breast Cancer
Addition of Bevacizumab to Chemotherapy in Platinum-Sensitive Ovarian Cancer
GU Symposium 2021: Neoadjuvant Gemcitabine, Cisplatin, and Pembrolizumab in Bladder Cancer
GU Symposium 2021: Radiotherapy Plus Pembrolizumab for Oligometastatic Kidney Cancer
GU Symposium 2021: Adding Pembrolizumab to Radium-223 for Metastatic Castration-Resistant Prostate Cancer
Blood Clots: New Adverse Event With First Infusion of Obinutuzumab for CLL?
GU Symposium 2021: Neoadjuvant Durvalumab Plus Chemotherapy in Muscle-Invasive Urothelial Carcinoma
Nivolumab as Neoadjuvant Therapy in High-Risk Clear Cell Renal Cell Carcinoma
WCLC 2020: 3-Year Survival Update on Pembrolizumab for Locally Advanced or Metastatic NSCLC
TCT 2021: Natural Killer Cell Therapy Under Study in Selected Patients With AML
GU Symposium 2021: Updated CheckMate 9ER Results on Nivolumab Plus Cabozantinib in Kidney Cancer
WCLC 2020: 5-Year Survival Update on Pembrolizumab Versus Docetaxel in NSCLC
WCLC 2020: Pembrolizumab Plus Chemotherapy for Metastatic NSCLC

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.